Please login to the form below

Not currently logged in
Email:
Password:

apixaban

This page shows the latest apixaban news and features for those working in and with pharma, biotech and healthcare.

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

UPDATED: BMS completes $13.1bn acquisition of MyoKardia

This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... Although BMS maintained at the time that the patent for composition of matter covering apixaban in the

Latest news

More from news
Approximately 9 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor. ... statistically significant reduction in mortality was also observed in apixaban recipients in this trial.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics